Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentrations

Kroegel, Claus; Foerster, Martin; Lerche, K; Aalamian-Mattheis, Maryam; Happe, Janett; Moeser, Anne; Korn, Stephanie

doi:10.1183/13993003.congress-2015.pa2561

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, very probably omalizumab influences also late phases of allergic reaction and the complex processes of airway remodelling. 52,66 Omalizumab furthermore (1) reduces the levels of the free fraction of IgE 67 (while it paradoxically increases the levels of total IgE (up to 5 times) as a result of increased stability and extended biological half-life of the bound molecules) 68 and, at the same time, (2) inhibits the expression of FcεRI on the surface of mast cells, Langerhans cells, eosinophils and basophils, indirectly reducing their reactivity to allergenic stimuli. 69 In addition to that (3) omalizumab also decreases the surface expression of IL-4R and germline Cε mRNA levels of B-lymphocytes which together reduces their responsiveness to antigenic stimulation and further the production of IgE.…”

Section: Possibilities Of Targeted Therapeutic Affecting Of Ige Actionmentioning

confidence: 99%

Evolution of our view on the IgE molecule role in bronchial asthma and the clinical effect of its modulation by omalizumab: Where do we stand today?

Novosad

Krčmová

2020

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Bronchial asthma is a heterogeneous disease whose definition and treatment are based on evidence of variable airway obstruction and airway inflammation. Despite the enormous increase in the amount of information on the pathogenesis of this disease, diagnosis is still an unresolved problem, as we still lack sensitive and specific biomarkers. On the other hand, at the turn of the 20th and 21st century, there was a rapid development of therapeutic modalities based on the principle of biological therapy. The first authorized drug matching these characteristics was omalizumab – a monoclonal antibody directed against immunoglobulin E (IgE). It has been used for the treatment of severe forms of bronchial asthma for more than 15 years, which is a sufficient time to acquire ways of its effective use and to assess whether the treatment with omalizumab has met our expectations. However, we continue to discover new and surprising facts about the effects of omalizumab treatment which leads to widening of therapeutic indications. In this work, a basic overview of the very complex role of the IgE molecule in the organism (with a special emphasis on allergic asthma) is discussed, and the most important practical and clinical consequences resulting from its modulation by targeted therapy with omalizumab are summarized.

show abstract

Section: Possibilities Of Targeted Therapeutic Affecting Of Ige Actionmentioning

confidence: 99%

Evolution of our view on the IgE molecule role in bronchial asthma and the clinical effect of its modulation by omalizumab: Where do we stand today?

Novosad

Krčmová

2020

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentrations

Cited by 1 publication

References 0 publications

Evolution of our view on the IgE molecule role in bronchial asthma and the clinical effect of its modulation by omalizumab: Where do we stand today?

Evolution of our view on the IgE molecule role in bronchial asthma and the clinical effect of its modulation by omalizumab: Where do we stand today?

Contact Info

Product

Resources

About